379 related articles for article (PubMed ID: 28469731)
1. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.
Hou P; Liu D; Xing M
Endocr Relat Cancer; 2011 Dec; 18(6):687-97. PubMed ID: 21937738
[TBL] [Abstract][Full Text] [Related]
5. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
[TBL] [Abstract][Full Text] [Related]
7. High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma.
Barros-Filho MC; Marchi FA; Pinto CA; Rogatto SR; Kowalski LP
J Clin Endocrinol Metab; 2015 Jun; 100(6):E890-9. PubMed ID: 25867809
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
9. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
10. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
11. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
12. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
14. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
16. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.
Zhang S; Wang Y; Chen M; Sun L; Han J; Elena VK; Qiao H
Sci Rep; 2017 Mar; 7():44033. PubMed ID: 28272462
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
Huang Y; de la Chapelle A; Pellegata NS
Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
[TBL] [Abstract][Full Text] [Related]
20. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]